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Background: Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease (CLD). About
80% of those exposed to the virus develop a chronic infection. Hyperhomocysteinemia, which is an independent
risk factor for atherosclerotic vascular disease and thromboembolism, may develop in HCV-infected patients
although altered alanine amino transferase (ALT) enzyme levels are generally associated with damage to liver cells.
The gold standard therapy for chronic hepatitis C patients is pegylated interferon combined with an anti-viral drug
(ribavirin). The current study aimed to investigate the effect of antiviral therapy on plasma homocysteine (Hcy)
levels in HCV patients in addition to other parameters.
Methods: 532 HCV-infected patients and 70 healthy controls were recruited for the study. All patients were
subjected to laboratory investigations including HCV-RNA levels, complete blood cell counts, serum levels of
homocysteine, ALT, alkaline phosphatase (ALP), lipid profile and liver ultrasonographic examination. The outcome of
treatment with pegylated interferon α plus ribavirin treatment and sustained virologic response (SVR) was
determined 6–9 months post-therapy.
Results: Hyperhomocysteinemia was found in 91.35% of HCV-infected patients. The difference in plasma Hcy
concentrations reached statistical significance between the patient and control groups. ALT, cholesterol and
triglycerides (TGs) levels were found higher than normal in the patients group. After receiving a combined therapy
for 24 weeks, 43.66% patients showed an SVR (responders); 30.98% patients were non-responders while 25.35%
patients initially responded to therapy but again retrieved positive status of HCV infection six months post-therapy
(relapse-cirrhotic patients). The mean levels of plasma Hcy, ALT and ALP were significantly reduced in responders
within 10 weeks of therapy when compared with non-responders and relapse-cirrhotic patients.
Conclusion: Elevated homocysteine levels in serum due to HCV infection can be reduced to normal range with the
standard interferon α plus ribavirin treatment. This study highlights the significance of the measurement of serum
homocysteine levels in the diagnosis and monitoring of HCV infection treatment in addition to other laboratory
parameters.
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Chronic infection with hepatitis C virus (HCV) is one of
the leading causes of chronic liver disease; about 170
million people worldwide are estimated to be infected.
Hepatitis C virus infection causes acute symptoms in
only 15% of patients exposed to HCV infection while
about 80% patients develop chronic infection [1].
Chronic hepatitis C results in formation of high levels
of free radicals in the liver cells, which put serious oxi-
dative stress depleting protective antioxidants and even-
tually kill the liver cells. Chronic hepatitis C infection
progresses very slowly and is marked by episodes of
acute hepatitis characterized by liver inflammation and
elevated ALT levels. A hepatitis screen is recommended
for patients whereby the disease can be diagnosed by
the presence of antibodies for hepatitis C or by the
direct presence of the virus or viral products in the
blood [2]. Serum levels of liver enzymes such as alanine
aminotransferase (ALT), aspartate aminotransferase
(AST) and alkaline phosphatase (ALP) are analyzed to
estimate damage caused to liver. Elevated ALT, AST &
ALP are associated with varying degrees of damage to
the liver cells [3].
Homocysteine levels are also altered in chronic liver
disease. Homocysteine is a sulphur-containing amino
acid belonging to the group of intracellular thiols.
Numerous clinical and epidemiological studies have
reported that elevated plasma homocysteine concentra-
tions reflect impaired cellular metabolism [4] and may
be considered as an independent risk factor for athero-
sclerotic vascular disease and thromboembolism [5].
Experimental data in transgenic mice deficient in homo-
cysteine metabolism enzymes have shown the presence
of severe liver steatosis with occasional steatohepatitis.
In human beings, many studies have found a correlation be-
tween homocysteine and steatosis. Hyperhomocysteinemia
may result from defects in homocysteine-metabolizing
genes; vitamin B6, B12, or folate deficiencies resulting
from nutritional conditions; or chronic alcohol con-
sumption [6].
Homocysteine is mainly synthesized and metabolized
in the liver, since metabolism of majority of dietary me-
thionine occurs in this organ, where about 85% of the
whole body capacity for transmethylation resides. There-
fore, genes involved in methionine and homocysteine
metabolism are expressed in a specific pattern in the
liver [7]. Homocysteine is formed as an intermediate in
methionine metabolism; therefore, impaired liver func-
tion leads to altered methionine and homocysteine
metabolism [8].
The gold standard therapy for chronic hepatitis C virus-
infected patients is a combined therapy with interferon
(pegylated interferon) and an anti-viral drug (ribavirin).
The first trial of interferon as therapy for chronic non-A,non-B hepatitis was reported in 1986. A sustained virolo-
gic response (SVR; clearance of serum HCV-RNA after six
months of therapy) results from combined therapy with
both pegylated interferon and ribavirin in 28% to 50% of
patients with genotype 1, while in patients with geno-
type 2, sustained response rates are higher (76% to 82%)
[9,10]. The recommended duration of treatment for
HCV genotypes 2 and 3 is 24 weeks and for genotype 1
is 48 weeks. Sustained virologic response is usually
accompanied by a return to normal serum ALT levels
and improvement in inflammation within the liver. Ap-
parently, the usual effect of interferon in patients with
chronic hepatitis C who respond to this therapy is viral
suppression but not eradication or cure. The genotype
and level of viremia are important factors that affect the
initial and long-term response to this therapy. The opti-
mal treatment for non-responders and relapsers is not
well established. However, it is expected that a minority
of non-responders (6% to 12%) may respond to a second
course of pegylated interferon and ribavirin [11].
The present study was conducted in Pakistan where
more than 10 million people are living with hepatitis C
virus with high morbidity and mortality. HCV preva-
lence is moderate in the general population (adults:
4.95% ± 0.53%; paediatric population: 1.72% ± 0.24%;
young population: 3.64% ± 0.31%) but very high in
injecting drug users (57% ± 17.7%) and multitransfused
patients (48.67% ± 1.75%). The most prevalent genotype
in Pakistan is 3a [12]. The aim of the current study was
to evaluate the effect of combined antiviral therapy
(interferon and ribavirin) on the concentrations of
plasma homocysteine in HCV patients.
Methods
Selection of subjects
Approval for the study was obtained from Quaid-i-Azam
University Institutional Review Board. Informed consent
was obtained from all subjects who participated in the
study. All the patients were positive for hepatitis C virus
infection while the control subjects were all healthy.
The patients were recruited from the Khan Research
Laboratories (KRL) hospital Islamabad. The patients
with hepatitis B virus infection, schistosomiasis,
chronic parenchymal and obstructive renal diseases
and alcohol abuse were excluded from the study. 532
patients (20–68 years; 272 males, 260 females) with
hepatitis C virus infection (Group I) and 70 healthy
control subjects (18–55 years; 42 males, 28 females;
Group II) were included in the study. All the patients
and controls were subjected to the following investi-
gations: thorough history taking and physical examin-
ation, laboratory tests including complete blood cell
counts (CBC), liver enzymes (ALT, AST & ALP), lipid
profile (serum cholesterol, triglycerides, HDL, LDL),
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tested positive for HCV-Ab), and plasma homocyst-
eine concentration. Abdominal ultrasound and liver
biopsy were performed for all subjects to evaluate
liver and exclude any renal parenchymal disease or
obstructive uropathy.
Treatment with interferon
The patients’ group was given interferon therapy: as a
first line of defence all the patients received 3 million
U of uniferon α-2B plus an antiviral drug ribazole
(1000 to1200 mg/day) for at least 24 weeks. A second
line of defence therapy (uniferon or pegasys plus ribazole)
was given after 6 months of completion of first dose
only to those patients who were either non-responders
or relapsed after first line of defence therapy.
Serum levels of HCV RNA were determined during a
follow-up period (6–9 months post-treatment) with use
of a reverse-transcriptase-PCR assay. All the patients
were again subjected to thorough physical examination,
lab tests, liver biopsy and abdominal ultrasound through
and after the period of medication.
Assessment of treatment efficacy
A sustained virologic response defined by the detectable
levels of HCV RNA in serum, 24 weeks after the end of
treatment was considered as primary end point. The
absence of the detectable levels of HCV RNA in serum
at the end of therapy and the normalization of serum
ALT levels were considered as secondary end points.
Statistical analysis
All values were expressed as arithmetic mean± SD. The
difference of biochemical and other parameters betweenTable 1 Base-line characteristics of controls and patients befo
Laboratory parameters Reference values
Hb (g/dl) M:13.5-18.0; F:11.5-16.5
PLT (*100) 150-450*100
TLC 4000-11000
ESR (mm/hr) M:0–10; F:0-15
ALT (U/L) M:0–40; F:0-37
ALP (U/L) 60-306





***: extremely statistically significant; **: very statistically significant; *: statistically si
total leukocyte count; ESR: erythrocyte sedimentation rate; ALT: alanine amino trans
lipids; TGs: triglycerides; Hcy: homocysteine.the control and patient groups before treatment was
tested for statistical significance using t-test. For overall
comparisons, one-way analysis of variance (ANOVA)
was used. The difference in serum homocysteine and
liver enzyme levels between differently responding-
patient groups after interferon treatment was investi-
gated by Tukey’s honestly significant difference (HSD)
test. P-value ≤ 0.0001 was considered extremely statisti-
cally significant, ≤ 0.001 as very statistically significant
and ≤ 0.01 as statistically significant.Results
Hyperhomocysteinemia and serum ALT levels before
interferon treatment
We studied 532 HCV-infected patients (272 males;
260 females) and 70 healthy individuals (42 males; 28
females) were enrolled as controls. Hyperhomocystei-
nemia was defined as plasma Hcy level > 15 μmol/L.
Hyperhomocysteinemia was observed in 486 patients
(253 males; 233 females). The mean level of plasma
Hcy was significantly higher in the patients group
(25.66 + 8.89) when compared to the control group
(12.36 + 1.64). The difference in plasma Hcy concen-
trations reached statistical significance between the
control and patient groups (Table 1; Figure 1). ALT
levels were found higher than normal in the patients’
group (110.47 ± 128.85). Cholesterol and triglyceride
levels were also elevated in the patients.Hyperhomocysteinemia and serum ALT levels after
interferon treatment
On the basis of the effect of combined antiviral therapy
given, the individuals in the patients’ group who were
available for follow-up after treatment (n = 355; 177re antiviral treatment
Control Group (n= 70) Patients Group (n= 532) P
14.19 ± 1.65 13.01 ± 1.98 <0.0001***
276.64 ± 75.31 545.79 ± 85.38 <0.0001***
6.14 ± 1.53 5.62 ± 2.36 =0.01*
13.18 ± 1.47 37.63 ± 22.34 <0.0001***
33.2 ± 7.45 110.47 ± 128.85 <0.0001***
214.61 ± 64.23 259.64 ± 64.07 <0.0001***
.22 4.67 ± 0.36 5.6 ± 0.76 <0.0001***
1.11 ± 0.16 1.30 ± 0.44 <0.0001***
2.92 ± 0.29 3.27 ± 0.72 <0.0001***
1.31 ± 0.49 2.10 ± 0.70 <0.0001***
12.36 ± 1.64 25.66 ± 8.89 <0.0001***
gnificant; +: statistically non-significant. Hb: hemoglobin; PLT: platelets; TLC:
ferase; ALP: alkaline phosphatase; HDL: high density lipids; LDL: low density
Figure 1 Plasma homocysteine (Hcy) levels in patients and controls.
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divided into three subgroups as responders (group I:
n = 155; 43.66%), non-responders (group II: n = 110;
30.98%) and relapse-cirrhotic patients (group III: n = 90;
25.35%). Responders were the group of patients in which
HCV RNA was found below the detection limit or turns
to normal after completion of 24 weeks of interferon
therapy; non-responders were those HCV patients who
did not show a response to either first line or the subse-
quent second line of combined therapy; the third group








Hb (g/dl) 14.56194± 1.197414 18.1790909± 1.002574251
PLT (*100) 237.7032± 63.00476 130.724771± 36.55282113
TLC 6.129032± 1.145968 12.5654545± 2.160463608
ESR (mm/hr) 19.63226± 7.286368 40.6818182± 22.31177408
ALT1 (U/L) 118.5484± 36.21046 76.0727273± 23.96354613
ALT2 (U/L) 72.77419± 17.2674 121.154545± 32.52499007
ALT3 (U/L) 41.42581± 9.053914 181.327273± 48.44122687
ALP1 (U/L) 336.2516± 20.15414 304.045455± 12.09623974
ALP2 (U/L) 251.6258± 24.00545 340.227273± 10.83035074
ALP3 (U/L) 170.9484± 28.92799 380.763636± 12.85267778
CHOL (mmol/L) 4.643226± 0.535738 5.68090909± 0.426742613
HDL (mmol/L) 1.343226± 0.495305 1.29454545± 0.297955222
LDL (mmol/L) 3.343226± 0.531846 4.25636364± 0.408516509
TGs (mmol/L) 1.93871± 0.567792 2.27454545± 0.586614664
Hcy (μmol/L) 19.33652± 2.434538 44.0485455± 9.32508345
***: extremely statistically significant; **: very statistically significant; *: statistically si
total leukocyte count; ESR: erythrocyte sedimentation rate; ALT1, ALT2 & ALT3: alan
ALP1, ALP2 & ALP3: alkaline phosphatase levels before, during and after therapy, re
TGs: triglycerides; Hcy: homocysteine.completion of the interferon therapy, however, regained
HCV positive status after 6 months of completion of
therapy. The mean level of plasma Hcy was significantly
reduced in responders (group I; 19.33 ± 2.43), when
compared to non-responders (group II; 44.04 ± 9.32) and
relapse-cirrhotic patients (group III; 56.11 ± 14.63). The
difference in plasma Hcy concentrations reached statis-
tical significance among the three studied groups
(Table 2).
At the start of the treatment, the ALT and ALP levels
were higher than normal in the three treatment groups.ent patient groups after antiviral treatment




P I & II I &III II & III
11.22778± 1.300564 <0.0001*** <0.01* <0.01* <0.01*
122.9111± 35.38286 0.6+ - - -
6.246667± 1.324887 <0.0001*** <0.01* NS <0.01*
29.93333± 10.32592 <0.0001*** <0.01* <0.01* <0.01*
102 ± 68.31355 <0.0001*** <0.01* <0.05* <0.01*
82.44444± 56.79178 <0.0001*** <0.01* NS <0.01*
115.2889± 64.24326 <0.0001*** <0.01* <0.01* <0.01*
349.9111± 25.01624 <0.0001*** <0.01* <0.01* <0.01*
324.8778± 24.07938 <0.0001*** <0.01* <0.01* <0.01*
365.7222± 20.64849 <0.0001*** <0.01* <0.01* <0.01*
5.631111± 0.777007 <0.0001*** <0.01* <0.01* NS
1.357778± 0.444436 0.53+ - - -
3.153333± 1.103233 <0.0001*** <0.01* NS <0.01*
2.026667± 0.592424 <0.0001*** <0.01* <0.01* <0.01*
56.11422± 14.63146 <0.0001*** <0.01* <0.01* <0.01*
gnificant; +: statistically non-significant. Hb: hemoglobin; PLT: platelets; TLC:
ine amino transferase levels before, during and after therapy, respectively;
spectively; CHOL: cholesterol; HDL: high density lipids; LDL: low density lipids;
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ders (group I) While non responders did not show any
decline. The ALT and ALP levels were reduced in
relapse-cirrhotic patients (group III) following the ther-
apy but again elevated even after treated with a second
line of therapy (Table 2; Figure 2).
Discussion
Our results indicated that plasma homocysteine levels
were significantly elevated in HCV-infected patients in
both sexes compared with control values. These find-
ings are in accordance with the results of Taha et al.
who observed elevated plasma homocysteine levels in
patients with liver cirrhosis secondary to hepatitis C
virus infection [4]. Garacia et al. attributed this condi-
tion to reduced expression of genes involved in HcyFigure 2 a) Comparative plasma ALT levels in different patient group
ALP levels in different patient groups at different stages of interferon therametabolism. The degree of reduced expression of these
genes was related to the severity of liver disease [6]. The
hyperhomocysteinemia is known as atherogenic and
thrombotic risk factor for cardiovascular disease. It
might also be a risk factor for cirrhotic patients but the
direct effect of Hcy on liver injury is not well known
[13]. Hyperhomosysteinemia was correlated with ele-
vated levels of ALT, ALP, TGs and cholesterol in the
current study. This might be related to progression of
liver injury. Some other studies have also reported a cor-
related elevation of plasma Hcy levels with ALT, ALP,
TGs and cholesterol [14,15]. It is evident that
homocysteine-induced endoplasmic reticulum stress
leaves a dysregulated endogenous sterol response path-
way, which leads to increased hepatic biosynthesis and
uptake of cholesterol and triglycerides [16].s at different stages of interferon therapy. b) Comparative plasma
py.
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apy of interferon with an antiviral drug for the treatment
of hepatitis C virus infection and recovery of Hcy, ALT
and ALP levels to normal. Interferon-α (IFN-α) is a cyto-
kine having multiple biological functions, which includes
antiviral and immunomodulatory activities [17], and is
commonly used for the treatment of patients with chronic
HCV infection. It has been evident from the results of re-
cent clinical reports that IFN-α treatment is effective in
decreasing serum ALT levels, reducing and eliminating
serum HCV RNA, and improving liver histology in
patients with chronic hepatitis C [18-22]. We performed a
comparative analysis of sustained virologic response
(clearance of serum HCV-RNA after six months of ther-
apy), homocysteinemia, serum ALT and ALP levels in
HCV-infected patients. Consequently, a positive response
was observed in 43.66% patients as indicated by undetect-
able serum HCV RNA (SVR), normal homocysteine, ALT
and ALP levels (referred to as responders). Other (25.35%)
patients shown positive response to therapy initially but
again retrieved HCV positive status (relapse-cirrhotic
patients). The therapy remained ineffective in 30.98%
patients (non-responders). Increased homocysteine levels
(>16 μmol/L) represent a factor associated with a lower
rate of SVR. Association between high homocysteine
levels and increased oxidative stress on cells partially
explains this effect [23]. It has been reported that homo-
cysteine transsulfuration through cystathionine-β-
synthase (CBS) activity as well as its remethylation
through betaine-dependent methyltransferase (BHMT)
activity are restricted to the liver [24]. Hence, an increase
in homocysteine levels could be the result of reduced ac-
tivities of these enzymes in patients with liver diseases, as
reported in the present study.
In the current study, anti-viral treatment for 24 weeks
was sufficient in HCV-infected patients to achieve SVR,
since a second line of therapy for prolonged periods was
still inefficient to reduce viremia in relapse-cirrhotic
patients. Even shorter periods of treatment might also
be sufficient in patients whom serum levels of HCV
RNA quickly become undetectable. These findings are in
line with the results of Jaeckel et al. [15]. The present
study also confirmed that the combination treatment
(standard interferon α plus ribavirin) can eliminate virus
in about half of HCV-infected patients [25].
As mentioned earlier that genotype 3a is the most
prevalent HCV genotype in the local population, we can
presume that findings of the current study predomin-
antly correlate with genotype 3a and should not be extra-
polated to other genotypes without further research.
Conclusion
We studied the effect of standard antiviral therapy
(interferon α plus ribavirin) on different laboratoryparameters in HCV patients in Pakistan. Liver enzymes
and homocysteine levels, which are elevated in the
serum of HCV patients beyond reference values (indi-
cated for normal individuals), were reduced to normal
limits after the treatment. However, the overall efficacy
of standard antivirus therapy in multigenotype subjects
remained low (~43%) that warns the need of more effi-
cient drugs with better efficacy. The study strengthens
the evidence that supports the significance of serum
homocysteine levels in the diagnosis and monitoring of
HCV infection treatment in addition to other laboratory
parameters. Further studies in different HCV genotypes
are suggested to establish serum homocysteine level as a
biomarker.
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